Ipilimumab-induced hypophysitis, a single academic center experience

[1]  F. Hodi,et al.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. , 2018, Endocrine reviews.

[2]  Y. Zakharia,et al.  Advanced stage melanoma therapies: Detailing the present and exploring the future. , 2019, Critical reviews in oncology/hematology.

[3]  R. Sullivan,et al.  High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma , 2018, Cancer.

[4]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Barry,et al.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA Oncology.

[6]  A. Hoff,et al.  Endocrine side effects of cancer immunotherapy. , 2017, Endocrine-related cancer.

[7]  D. Schadendorf,et al.  Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. , 2017, The Lancet. Oncology.

[8]  M. Cosottini,et al.  Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. , 2016, The American journal of pathology.

[9]  M. Murad,et al.  Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[10]  A. Faje.  Hypophysitis: Evaluation and Management , 2016, Clinical Diabetes and Endocrinology.

[11]  P. Carroll,et al.  Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review , 2016, Clinical endocrinology.

[12]  A. Faje.  Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights , 2016, Pituitary.

[13]  J. Grob,et al.  Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. , 2015, European journal of endocrinology.

[14]  A. Giobbie-Hurder,et al.  Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study , 2014, Clinical Cancer Research.

[15]  R. Sullivan,et al.  Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. , 2014, The Journal of clinical endocrinology and metabolism.

[16]  P. Marchetti,et al.  Endocrine side effects induced by immune checkpoint inhibitors. , 2013, The Journal of clinical endocrinology and metabolism.

[17]  S. Corsello,et al.  Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. , 2012, The oncologist.

[18]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[19]  C. Yedinak,et al.  Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes , 2009, Pituitary.

[20]  田攀文,et al.  Autoimmune hypophysitis , 2007 .

[21]  John A. Jane,et al.  Hypophysitis , 2006, Pituitary.

[22]  S. Rosenberg,et al.  Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma , 2006, Journal of immunotherapy.

[23]  A. Olivi,et al.  Autoimmune hypophysitis. , 2020, Endocrine reviews.